Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review1012 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.First antagonist of mGlu6, the group III mGlu receptor found in the retina.
M. Wt | 199.1636 |
Storage | Desiccate at -20°C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
Thoreson et al (1997) Two phenylglycine derivatives antagonize responses to L-AP4 in ON bipolar cells of the amphibian retina. Neuropharmacology 36 1 PMID: 9144636
View all Glutamate (Metabotropic) Group III Receptor Antagonists
Keywords: (RS)-3,4,5-THPG, (RS)-3,4,5-THPG supplier, Glutamate, (Metabotropic), Group, III, Receptors, 1012, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-3,4,5-THPG.
There are currently no reviews for this product. Be the first to review (RS)-3,4,5-THPG and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.